NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

Diagnostics Advisory Committee (DAC) meeting minutes

**Minutes:** Confirmed

**Date and time:** Thursday 18 January 2024 at 10:00

**Location:** Via Zoom

# Committee members present:

Brian Shine (Chair) Present for all items

Neil Hawkins (Vice Chair) Present for all items

Rebecca Allcock Present for all items

Joy Allen Present for all items

John Cairns Present for all items

Sam Creavin Present for all items

Diane Davies Present for all items

Farai Goromonzi Present for all items

Rashmi Kumar Present for all items

Patrick McGinley Present for all items

Alex Novak Present for all items

Radha Ramachandran Present for all items

Anne Scott Present for all items

Matt Stevenson Present for all items

Jonathan Weir-McCall Present for all items

# NICE staff present:

Rebecca Albrow, Associate Director, Diagnostics Assessment Present for all items

Frances Nixon, Health Technology Assessment Adviser, Present for all items

Diagnostics Assessment

Anam Khan, Health Technology Assessment Analyst, Present for all items

Diagnostics Assessment

Toni Gasse, Project Manager, Diagnostics Assessment Present for all items

Elaine Sale, Administrator, Diagnostics Assessment Present for all items

Janine Wigmore, Public Involvement Programme Adviser Present for all items

Lyn Davies, Meetings In Public Coordinator Present for all items

Edgar Masanga, Resource Impact Present for all items

# External assessment group representatives present:

Mark Simmonds, Senior Research Fellow, University of York Present for items 1 to 4.1.6

Matthew Walton, Research Fellow, University of York Present for items 1 to 4.1.6

# Specialist committee members present:

Roger Aldridge, Consultant Plastic Surgeon & Consultant Present for all items

Dermatological Surgeon, NHS Lanarkshire & NHS Lothian

Stephanie Gallard, Dermatology GPSI for the Liverpool Present for all items

ICATS, Liverpool University FT

Kate Hawley, Specialist Lay Committee Member Present for all items

Eugene Healy, Head of Dermatology and Present for all items

Department Chair, Southampton General Hospital

Nalayini Kumaralingam, Nurse Consultant, Present for items 1 to 4.1.6

Kent Oncology Centre, Maidstone Hospital

Rubeta Matin, Consultant Dermatologist, Present for items 1 to 4.1.6

Oxford University Hospitals NHS Trust

Stephen McKenna, Professor, Research Cluster Lead Present for items 1 to 4.1.6

(Computer Sciences and Informatics), University of Dundee

Susan Mountain, Specialist Lay Committee Member Present for all items

# Observers present:

Matthew Brown, Digital Media Manager, NICE Present for all items

Ruth Melville, Senior Medical Editor, NICE Present for all items

Ziqi Zhou, Health Technology Assessment Analyst, NICE Present for all items

Charlotte Fairclough, Technical Analyst, NICE Present for all items

Tom Lawrence, Technical Adviser - Data Scientist, NICE Present for all items

Stephen Duffield, Associate Director, NICE Present for all items

Michael Merchant, Senior Analyst, NICE Present for all items

Anne Murray-Cota, Senior Analyst, NICE Present for all items

James Le Fevre, Emergency Medical Specialist, Auckland Present for all items

District Health Board, New Zealand

1. Introduction to the meeting
	1. The chair welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Keith Abrams, Ghada Ahmed, Michael Morton and John Lear.
2. News and announcements
	1. None.
3. Minutes from the last meeting
	1. The committee approved the minutes of the committee meeting held on 29 November 2023.
4. Evaluation of Artificial Intelligence technologies for assessing skin lesions selected for referral on the urgent suspected cancer pathway to detect benign lesions and reduce secondary care specialist appointments: Early Value Assessment
	1. Part 1 – Open session
		1. The chair welcomed specialist committee members, external assessment group representatives, members of the public and company representatives from Skin Analytics and FotoFinder Systems Ltd.
		2. The chair asked all committee members and specialist committee members to indicate if they had any further interests to declare, in addition to those declared in advance of the meeting. All interests declared for this assessment are listed on the registers available on the NICE website here: [Project information | Artificial intelligence (AI) technologies for assessing skin lesions referred on the urgent suspected cancer pathway | Guidance | NICE](https://www.nice.org.uk/guidance/indevelopment/gid-hte10047)
		3. **DAC 1:** The Committee proceeded to discuss the clinical effectiveness and cost effectiveness of **Artificial Intelligence technologies for assessing skin lesions selected for referral on the urgent suspected cancer pathway to detect benign lesions and reduce secondary care specialist appointments: Early Value Assessment**.

The Committee was asked if there were any specific equality issues to consider in relation to this assessment.

* + 1. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
		2. The Chair thanked the external assessment group, company representatives, and public observers for their attendance at the meeting.
		3. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and the external assessment group, manufacturer representatives and public observers left the meeting.
	1. Part 2 – Closed session
		1. The committee discussed confidential information submitted for this item.
		2. The committee discussed next steps.
		3. The committee then agreed on the content of the Diagnostics Consultation Document (DCD). The committee decision was reached by consensus..
		4. The committee asked the NICE technical team to prepare the Diagnostics Consultation Document (DCD) in line with their decisions.
1. Date of the next meeting

The next meeting of the Diagnostics Advisory Committee (DAC) will be held on 12 March 2024 and will start promptly at 9am.